Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain
The adhesive capsaicin dermal patch (Qutenza®) delivers a high concentration (8% w/w) of synthetic capsaicin, a highly selective agonist of transient receptor potential vanilloid-1 (TRPV-1), directly to the site of pain. The capsaicin 8% dermal patch is indicated in the EU for the treatment of peripheral neuropathic pain (PNP) in adults, either alone or in combination with other medicinal products for pain. In patients with painful diabetic peripheral neuropathy, a single 30-min application of the capsaicin 8% dermal patch provided 12 weeks of pain relief and improved sleep quality compared with placebo. Repeat treatment with the capsaicin 8% dermal patch plus standard of care over 52 weeks provided sustained pain relief, with no negative neurological effects compared with standard of care alone. The capsaicin 8% dermal patch was non-inferior to oral pregabalin in relieving pain in patients with non-diabetic PNP, with a faster onset of action and greater treatment satisfaction. A single 60-min application of the capsaicin 8% dermal patch provided rapid and sustained pain relief in patients with postherpetic neuralgia. Results in patients with HIV-associated neuropathy were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8% dermal patch was generally well tolerated; transient application-site reactions were the most common adverse events. In conclusion, the capsaicin 8% dermal patch is a useful addition to the treatment options currently available for patients with PNP.
During the peer review process, the manufacturer of capsaicin 8% dermal patch was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of Interest
Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 6.European Medicines Agency. Summary of product characteristics: Qutenza 179 mg cutaneous patch. 2017. http://www.ema.europa.eu. Accessed 10 Sep 2018.
- 11.European Medicines Agency. CHMP assessment report for Qutenza. 2009. http://www.ema.europa.eu. Accessed 10 Sep 2018.
- 14.Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(251):1–14.Google Scholar
- 15.Perrot S, Ortega E, Vinik EJ, et al. Efficacy, quality of life and treatment satisfaction with capsaicin 8% patch versus standard of care in painful diabetic peripheral neuropathy [abstract no. 1067]. Diabetologia. 2015;58(Suppl. 1):S514.Google Scholar
- 26.Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–83.CrossRefGoogle Scholar
- 29.Mankowski C, Poole CD, Ernault E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17(80):1–11.Google Scholar
- 31.Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(162):1–5.Google Scholar
- 33.Aitken E, McColl G, Kingsmore D. The role of Qutenza® (topical capsaicin 8%) in treating neuropathic pain from critical ischemia in patients with end-stage renal disease: an observational cohort study. Pain Med. 2017;18(2):330–40.Google Scholar
- 35.Marec CLE, Berard J, Queneuille I, et al. Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch [abstract no. e14031]. J Clin Oncol. 2016;34(15 Suppl).Google Scholar
- 36.Reeves K, Tilak D, Putt O. Is an 8% capsicum patch (Qutenza) an alternative to traditional neuropathic pain management following breast surgery [abstract no. 138460]? Reg Anesth Pain Med. 2016;41(5 Suppl.):e116.Google Scholar
- 38.Churruca I. Capsaicin 8% patch in urological patients with neuropathic pain [abstract no. WIP16-0048]. Pain Pract. 2016;16(Suppl. 1):48.Google Scholar
- 39.Churruca I, Miro P, Pardina A, et al. Capsaicin (8%) patch in urological patients with neuropathic pain due to scar [abstract]. In: 9th World Congress of the World Institute of Pain. 2018.Google Scholar
- 40.Gustorff B, Poole C, Kloimstein H, et al. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand J Pain. 2017;4(3):138–45.CrossRefGoogle Scholar
- 48.National Institute for Health and Care Exellence (NICE). Neuropathic pain—pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings (updated February 2017). 2013. http://www.nice.org.uk/guidance/cg173. Accessed 10 Sep 2018.